27 Aug Propeller Health to enter Japanese market
Madison-based Propeller Health will begin distributing its digital health platform in Japan to patients using two Novartis inhaler medications to treat uncontrolled asthma — the first step in entering Japan’s market.
“In Japan, our market entry is occurring in partnership with Novartis, so right now we’re only available in Japan for patients who use Enerzair or Atectura Breezhaler to manage their asthma,” said Propeller spokesperson Rachel Fields.
Enerzair Breezhaler was approved in Japan on June 29 for the treatment of bronchial asthma.
Sorry, the comment form is closed at this time.